α/β CD3+/CD19+ cell depleted stem cell therapy (New York Medical College)

N/A

Report date: 2024/07/26 16:16:59

Base Information

Drug Nameα/β CD3+/CD19+ cell depleted stem cell therapy (New York Medical College)

Drug Alias Nameallogenic alpha/beta CD3+ T cell and CD19+ B cell depleted stem cells (New York Medical College)清除CD3 T淋巴细胞（αβT细胞）和CD19 B细胞的干细胞制剂-纽约医学院

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy

Mechanisms of ActionStem cell replacementsT cell surface glycoprotein CD3 modulatorsB-lymphocyte antigen CD19 modulators

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19

Therapy Area/IndicationsKostmann SyndromeThrombocytopeniaThalassemia +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNew York Medical College

China Registration ClassN/A

Develop Information

Active CompaniesNew York Medical College

Inactive CompaniesN/A

Active IndicationsKostmann SyndromeThrombocytopeniaThalassemia +[9]

Inactive IndicationsN/A

Other Information

ATC CodeN/A